Clara Biotech vs Esco Aster: CDMO Comparison
Side-by-side comparison of Clara Biotech and Esco Aster on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
What to evaluate for Exosome programs
Both Clara Biotech and Esco Aster qualify as Exosome CDMOs. When choosing between them for Exosome programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Cell source & scale
Confirm the producer cell source and whether culture is suspension-adapted for the volumes EV yields demand.
Isolation & purification
Isolation method (tangential-flow filtration, chromatography) drives yield, purity, and scalability. Ask how it performs at your target scale.
Characterization & potency
EV characterization (particle count, size, cargo, identity) and potency assays are still maturing — look for established, qualified methods.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
Frequently asked: Clara Biotech vs Esco Aster
Which is better for Exosome manufacturing — Clara Biotech or Esco Aster?
Both Clara Biotech and Esco Aster are tagged as Exosome CDMOs in our directory, so both are credible options for Exosome programs. The most important differentiator for Exosome selection is typically cell source & scale: Confirm the producer cell source and whether culture is suspension-adapted for the volumes EV yields demand. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Clara Biotech carries a Signal Score of 56/100 and Esco Aster carries 63/100 — a small lead for Esco Aster. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →